CHEK1 and pulmonary fibrosis: Next, we evaluated the therapeutic efficacy of interfering with the PGAM1‒Chk1 interaction in aging-related disorders, as several other senolytic approaches, e.g., ABT263 or D + Q, reportedly alleviate these disorders.7 For this purpose, we focused on lung fibrosis models for several reasons.